{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:15Z","timestamp":1792788435717,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21DA050038"],"award-info":[{"award-number":["R21DA050038"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA015815"],"award-info":[{"award-number":["UG1DA015815"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057672"],"award-info":[{"award-number":["R01DA057672"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12HS026383"],"award-info":[{"award-number":["K12HS026383"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Urban Health"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>People experiencing homelessness (PEH) face a high risk of opioid-related deaths, yet there is limited qualitative data on the barriers encountered when accessing buprenorphine treatment for opioid use disorder (OUD). To address this gap, we interviewed 28 clinicians, outreach workers, and administrators from organizations serving PEH with OUD. Our goal was to understand the barriers and facilitators at the patient, clinic, and institutional levels and gather recommendations for improvement. Interviews, conducted via Zoom and analyzed through thematic analysis, revealed several barriers. At the patient level, themes related to barriers included knowledge and experience (e.g., limited knowledge about buprenorphine options; rejection of buprenorphine due to prior experience with precipitated withdrawal); concerns about the medication and its administration (e.g., distrust of injectable medications; concerns about treatment control, and a prolonged informed consent process for extended-release injectable buprenorphine); and challenges due to homelessness (e.g., identification requirement to access medication at pharmacies, difficulties managing buprenorphine while unsheltered). At the clinic level, themes centered around staffing (e.g., lack of training and experience in treating PEH and staffing shortages) and health care-related stigma (e.g., discriminatory attitudes toward PEH with OUD). Institutional-level themes included state-regulatory factors (e.g., practice regulations limiting clinical pharmacists\u2019 ability to prescribe buprenorphine) and access factors (e.g., stigmatization of buprenorphine prescribing, limited low-barrier buprenorphine access, and care system complexity). Recommendations included educational programs for patients and clinicians to increase understanding and reduce stigma, integrating buprenorphine treatment into non-traditional settings, and providing housing with treatment.<\/jats:p>","DOI":"10.1007\/s11524-025-00967-y","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T15:53:09Z","timestamp":1743349989000},"page":"465-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Barriers to Buprenorphine Treatment Among People Experiencing Homelessness: A Qualitative Study from the Provider Perspective"],"prefix":"10.1007","volume":"102","author":[{"given":"Carmen L.","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya Chi Angelina","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie W.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip O.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"1","key":"967_CR1","doi-asserted-by":"publisher","first-page":"e2142676","DOI":"10.1001\/jamanetworkopen.2021.42676","volume":"5","author":"DR Fine","year":"2022","unstructured":"Fine DR, Dickins KA, Adams LD, et al. Drug overdose mortality among people experiencing homelessness, 2003 to 2018. JAMA Netw Open. 2022;5(1):e2142676. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42676.","journal-title":"JAMA Netw Open"},{"key":"967_CR2","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2025.\u00a0https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed 28 Jul 2024."},{"key":"967_CR3","unstructured":"Centers for Disease Control and Prevention. The Fentalog study: a subset of nonfatal suspected opioid-involved overdoses with toxicology testing. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/fentalog-study-dashboard.html. Accessed 2 Aug 2024."},{"issue":"1","key":"967_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/00952990601091093","volume":"33","author":"KF Corsi","year":"2007","unstructured":"Corsi KF, Kwiatkowski CF, Booth RE. Treatment entry and predictors among opiate-using injection drug users. Am J Drug Alcohol Abuse. 2007;33(1):121\u20137. https:\/\/doi.org\/10.1080\/00952990601091093.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"967_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2018.08.024","volume":"193","author":"S Amiri","year":"2018","unstructured":"Amiri S, Hirchak K, Lutz R, et al. Three-year retention in methadone opioid agonist treatment: a survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Drug Alcohol Depend. 2018;193:63\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.024.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"967_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial. JAMA Intern Med. 2018;178(6):764\u201373. https:\/\/doi.org\/10.1001\/jamainternmed.2018.1052.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"967_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13722-019-0149-1","volume":"14","author":"J Carter","year":"2019","unstructured":"Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019;14(1):20. https:\/\/doi.org\/10.1186\/s13722-019-0149-1.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"967_CR8","doi-asserted-by":"publisher","first-page":"e210477","DOI":"10.1001\/jamanetworkopen.2021.0477","volume":"4","author":"DR Fine","year":"2021","unstructured":"Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. Office-based addiction treatment retention and mortality among people experiencing homelessness. JAMA Netw Open. 2021;4(3):e210477. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0477.","journal-title":"JAMA Netw Open"},{"key":"967_CR9","doi-asserted-by":"publisher","first-page":"108316","DOI":"10.1016\/j.jsat.2021.108316","volume":"126","author":"AM Peckham","year":"2021","unstructured":"Peckham AM, Kehoe LG, Gray JR, Wakeman SE. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series. J Subst Abuse Treat. 2021;126:108316. https:\/\/doi.org\/10.1016\/j.jsat.2021.108316.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"967_CR10","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1097\/ADM.0000000000001213","volume":"17","author":"K Lee","year":"2023","unstructured":"Lee K, Zhao Y, Merali T, et al. Real-world evidence for impact of opioid agonist therapy on nonfatal overdose in patients with opioid use disorder during the COVID-19 pandemic. J Addict Med. 2023;17(6):e374\u201381. https:\/\/doi.org\/10.1097\/ADM.0000000000001213.","journal-title":"J Addict Med"},{"key":"967_CR11","unstructured":"Creswell JW, Poth CN. Qualitative inquiry and research design: Choosing among five approaches.\u00a0Thousand Oaks, CA: Sage publications; 2016."},{"key":"967_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci IS. 2009;4:50. https:\/\/doi.org\/10.1186\/1748-5908-4-50.","journal-title":"Implement Sci IS"},{"key":"967_CR13","doi-asserted-by":"publisher","unstructured":"Corbin J, Strauss A. Basics of qualitative research (3rd Ed.): techniques and procedures for developing grounded theory. SAGE Publications, Inc.; 2008. https:\/\/doi.org\/10.4135\/9781452230153","DOI":"10.4135\/9781452230153"},{"key":"967_CR14","unstructured":"Dedoose Version 9.0.17, Web application for managing, analyzing, and presenting qualitative and mixed method research data. www.dedoose.com. Accessed 10 Aug 2024."},{"issue":"5","key":"967_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","volume":"41","author":"JP De Aquino","year":"2021","unstructured":"De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425\u201336. https:\/\/doi.org\/10.1007\/s40261-021-01032-7.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"967_CR16","doi-asserted-by":"publisher","first-page":"e1002969","DOI":"10.1371\/journal.pmed.1002969","volume":"16","author":"AC Tsai","year":"2019","unstructured":"Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLOS Med. 2019;16(11):e1002969. https:\/\/doi.org\/10.1371\/journal.pmed.1002969.","journal-title":"PLOS Med"},{"key":"967_CR17","doi-asserted-by":"publisher","first-page":"108752","DOI":"10.1016\/j.jsat.2022.108752","volume":"138","author":"N Swartz","year":"2022","unstructured":"Swartz N, Adnan T, Per\u00e9a F, Baggett TP, Chatterjee A. \u201cSick and tired of being sick and tired\u201d: exploring initiation of medications for opioid use disorder among people experiencing homelessness. J Subst Abuse Treat. 2022;138:108752. https:\/\/doi.org\/10.1016\/j.jsat.2022.108752.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"967_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","volume":"63","author":"JA Adams","year":"2023","unstructured":"Adams JA, Chopski NL, Adams AJ. Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act. J Am Pharm Assoc JAPhA. 2023;63(5):1495\u20139. https:\/\/doi.org\/10.1016\/j.japh.2023.06.001.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"14","key":"967_CR19","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s11606-022-07471-y","volume":"37","author":"D Qi","year":"2022","unstructured":"Qi D, Abri K, Mukherjee MR, et al. Health impact of street sweeps from the perspective of healthcare providers. J Gen Intern Med. 2022;37(14):3707\u201314. https:\/\/doi.org\/10.1007\/s11606-022-07471-y.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"967_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","volume":"10","author":"AD Fox","year":"2015","unstructured":"Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2. https:\/\/doi.org\/10.1186\/s13722-014-0023-0.","journal-title":"Addict Sci Clin Pract"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"209216","DOI":"10.1016\/j.josat.2023.209216","volume":"157","author":"M Hsu","year":"2024","unstructured":"Hsu M, Jung OS, Kwan LT, et al. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: voices from the streets. J Subst Use Addict Treat. 2024;157:209216. https:\/\/doi.org\/10.1016\/j.josat.2023.209216.","journal-title":"J Subst Use Addict Treat"},{"key":"967_CR22","doi-asserted-by":"publisher","first-page":"108781","DOI":"10.1016\/j.jsat.2022.108781","volume":"139","author":"C Matheson","year":"2022","unstructured":"Matheson C, Foster R, Schofield J, Browne T. Long-acting depot buprenorphine in people who are homeless: views and experiences. J Subst Abuse Treat. 2022;139:108781. https:\/\/doi.org\/10.1016\/j.jsat.2022.108781.","journal-title":"J Subst Abuse Treat"},{"key":"967_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","volume":"100","author":"D Muthulingam","year":"2019","unstructured":"Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: a needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18\u201328. https:\/\/doi.org\/10.1016\/j.jsat.2019.01.019.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"967_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/29767342231218529","volume":"45","author":"DR Fine","year":"2024","unstructured":"Fine DR, Critchley N, Hart K, et al. \u201cI\u2019m on the right path\u201d: exploring 1-month retention in a homeless-tailored outpatient-based opioid treatment program. Subst Use Amp Addict J. 2024;45(2):268\u201377. https:\/\/doi.org\/10.1177\/29767342231218529.","journal-title":"Subst Use Amp Addict J"},{"issue":"S3","key":"967_CR25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","volume":"35","author":"K Mackey","year":"2020","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(S3):954\u201363. https:\/\/doi.org\/10.1007\/s11606-020-06257-4.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"967_CR26","doi-asserted-by":"publisher","first-page":"e2146971","DOI":"10.1001\/jamanetworkopen.2021.46971","volume":"5","author":"A Kennedy-Hendricks","year":"2022","unstructured":"Kennedy-Hendricks A, McGinty EE, Summers A, Krenn S, Fingerhood MI, Barry CL. Effect of exposure to visual campaigns and narrative vignettes on addiction stigma among health care professionals: a randomized clinical trial. JAMA Netw Open. 2022;5(2):e2146971. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.46971.","journal-title":"JAMA Netw Open"},{"key":"967_CR27","unstructured":"Substance Abuse and Mental Health Services Administration. SAMHSA\u2019s guidance on the elimination of the X-waiver.; 2023.\u00a0https:\/\/www.samhsa.gov\/substance-use\/treatment\/statutes-regulations-guidelines\/mat-act. Accessed 10 Aug 2024."},{"issue":"3","key":"967_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.mayocpiqo.2024.04.004","volume":"8","author":"ST Savitz","year":"2024","unstructured":"Savitz ST, Stevens MA, Nath B, D\u2019Onofrio G, Melnick ER, Jeffery MM. Trends in the prescribing of buprenorphine for opioid use disorder, 2019\u20132023. Mayo Clin Proc Innov Qual Outcomes. 2024;8(3):308\u201320. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.04.004.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"4","key":"967_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/ADM.0000000000000943","volume":"16","author":"SA Simpson","year":"2022","unstructured":"Simpson SA, Hordes M, Blum J, Rinehart D, Al-Tayyib A. Barriers to engagement in opioid use disorder treatment after buprenorphine induction. J Addict Med. 2022;16(4):479\u201382. https:\/\/doi.org\/10.1097\/ADM.0000000000000943.","journal-title":"J Addict Med"},{"issue":"10","key":"967_CR30","doi-asserted-by":"publisher","first-page":"e2437233","DOI":"10.1001\/jamanetworkopen.2024.37233","volume":"7","author":"A Chatterjee","year":"2024","unstructured":"Chatterjee A, Stewart EA, Assoumou SA, et al. Health and economic outcomes of offering buprenorphine in homeless shelters in Massachusetts. JAMA Netw Open. 2024;7(10):e2437233. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37233.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"967_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1176\/appi.ps.70701","volume":"70","author":"C Buzza","year":"2019","unstructured":"Buzza C, Elser A, Seal J. A mobile buprenorphine treatment program for homeless patients with opioid use disorder. Psychiatr Serv. 2019;70(7):635\u20136. https:\/\/doi.org\/10.1176\/appi.ps.70701.","journal-title":"Psychiatr Serv"},{"key":"967_CR32","doi-asserted-by":"publisher","first-page":"108342","DOI":"10.1016\/j.jsat.2021.108342","volume":"127","author":"DT O\u2019Gurek","year":"2021","unstructured":"O\u2019Gurek DT, Jatres J, Gibbs J, Latham I, Udegbe B, Reeves K. Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting. J Subst Abuse Treat. 2021;127:108342. https:\/\/doi.org\/10.1016\/j.jsat.2021.108342.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"967_CR33","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1097\/ADM.0000000000000682","volume":"14","author":"M Harris","year":"2020","unstructured":"Harris M, Johnson S, Mackin S, Saitz R, Walley AY, Taylor JL. Low barrier tele-buprenorphine in the time of COVID-19: a case report. J Addict Med. 2020;14(4):e136\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000682.","journal-title":"J Addict Med"},{"issue":"1","key":"967_CR34","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/ADM.0000000000000809","volume":"16","author":"B Tofighi","year":"2022","unstructured":"Tofighi B, McNeely J, Walzer D, et al. A Telemedicine buprenorphine clinic to serve New York City: initial evaluation of the NYC public hospital system\u2019s initiative to expand treatment access during the COVID-19 pandemic. J Addict Med. 2022;16(1):e40\u20133. https:\/\/doi.org\/10.1097\/ADM.0000000000000809.","journal-title":"J Addict Med"},{"issue":"6","key":"967_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/ADM.0000000000000791","volume":"15","author":"M Komaromy","year":"2021","unstructured":"Komaromy M, Tomanovich M, Taylor JL, et al. Adaptation of a system of treatment for substance use disorders during the COVID-19 pandemic. J Addict Med. 2021;15(6):448\u201351. https:\/\/doi.org\/10.1097\/ADM.0000000000000791.","journal-title":"J Addict Med"},{"issue":"2","key":"967_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08897077.2021.1890676","volume":"42","author":"NJ Mehtani","year":"2021","unstructured":"Mehtani NJ, Ristau JT, Snyder H, et al. COVID-19: a catalyst for change in telehealth service delivery for opioid use disorder management. Subst Abuse. 2021;42(2):205\u201312. https:\/\/doi.org\/10.1080\/08897077.2021.1890676.","journal-title":"Subst Abuse"},{"issue":"6","key":"967_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/ADM.0000000000000989","volume":"16","author":"L Samuel","year":"2022","unstructured":"Samuel L, Caygill-Walsh R, Suen LW, Mohebbi S, Geier M. Triple threat: response to the crises of COVID-19, homelessness, and opioid use disorder with a novel approach to buprenorphine delivery: a case series. J Addict Med. 2022;16(6):733\u20135. https:\/\/doi.org\/10.1097\/ADM.0000000000000989.","journal-title":"J Addict Med"},{"issue":"1","key":"967_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","volume":"14","author":"ME Godersky","year":"2019","unstructured":"Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14(1):11. https:\/\/doi.org\/10.1186\/s13722-019-0139-3.","journal-title":"Addict Sci Clin Pract"}],"container-title":["Journal of Urban Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11524-025-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11524-025-00967-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11524-025-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:28:15Z","timestamp":1745587695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11524-025-00967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s11524-025-00967-y","relation":{},"ISSN":["1099-3460","1468-2869"],"issn-type":[{"value":"1099-3460","type":"print"},{"value":"1468-2869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"22 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}